[Protective effect of pyrrolidine dithiocarbamate on erythrocytes during canine cardiopulmonary bypass].
OBJECTIVE
To investigate the protective effect of pyrrolidine dithiocarbamate (PDTC) on erythrocytes during canine cardiopulmonary bypass (CPB).


METHODS
Twelve adult healthy dogs undergoing CPB were randomly divided into the control group (n = 6) and the PDTC group (n = 6). In the PDTC group, PDTC 30 mg/kg was administered intravenously before CPB. Dogs in the control group was intravenously administering with normal saline. The levels of interleukin (IL)-1beta, IL-8, malondiadehyde (MDA), free hemoglobin (F-HB) in plasma, erythrocyte adenosine triphosphate (E-ATP), and erythrocyte superoxide dismutase (E-SOD) were determined before CPB, 30 and 60 minutes after aortic cross-clamping (AC), and 30 and 60 minutes after declamping (DC).


RESULTS
In the control group, plasma levels of IL-1beta and IL-8 significantly increased after CPB (P < 0.01). In the PDTC group, plasma levels of IL-1beta and IL-8 significantly increased after CPB (P < 0.05, P < 0.01). Plasma levels of MDA and F-HB significantly increased (P < 0.01) and the E-ATP level and E-SOD activity significantly decreased after CPB (P < 0.01) in both two groups. The E-ATP level and E-SOD activity in the PDTC group at 30 and 60 minutes after AC and 30 and 60 minutes after DC were significantly higher than those in control group (P < 0.01). However, the levels of IL-1beta, IL-8, MDA, and F-HB at 30 and 60 minutes after AC and 30 and 60 minutes after DC were significantly lower in the PDTC group than those in control group (P < 0.01).


CONCLUSIONS
PDTC can protect erythrocytes by alleviating lipid peroxidation and inflammatory response during CPB.
Fang
Hua
H
Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610041, China. succiniter@hotmail.com
Liu
Jin
J
Li
Chang-Xi
CX
Wang
Quan-Yun
QY
Zuo
Yun-Xia
YX
D000818:Animals; D002315:Cardiopulmonary Bypass / Q000379:methods*; D004285:Dogs; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D053583:Interleukin-1beta / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects; D008315:Malondialdehyde / Q000097:blood; D011759:Pyrrolidines / Q000627:therapeutic use*; D011897:Random Allocation; D013859:Thiocarbamates / Q000627:therapeutic use*
D006454:Hemoglobins; D053583:Interleukin-1beta; D016209:Interleukin-8; D011759:Pyrrolidines; D013859:Thiocarbamates; C020972:pyrrolidine dithiocarbamic acid; D008315:Malondialdehyde